1. Home
  2. News
  3. Mesoblast Limited
  4. Major Milestone Treatment Completed in P3 Trial for CLBP
More Mesoblast Limited news
Mesoblast LimitedASX: MSB

Major Milestone Treatment Completed in P3 Trial for CLBP

Aug 16, 2026 at 8:21 PM EDT · Issued by Mesoblast Limited

Filed with ASX · Aug 16, 2026 at 8:21 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/major-milestone-treatment-completed-in-p3-trial-for-clbp

Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26↗

Mesoblast Limited on 6ix

Story so far

  • Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back PainJul 14, 2026
  • Pivotal Phase 3 Trial in CLBP Achieves 300 Treated PatientsJul 14, 2026
  • Patient Recruitment Target Achieved in CLBP Pivotal TrialApr 29, 2026

Earlier from Mesoblast

  • Becoming a substantial holderAug 13
  • Ceasing to be a substantial holderAug 7
  • Quarterly Activities/Appendix 4C Cash Flow ReportJul 29
  • Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product LaunchJul 29
  • Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back PainJul 13

Later from Mesoblast

  • Mesoblast 2026 Full Year Financial Results WebcastAug 24
  • Notification regarding unquoted securities - MSBAug 24
  • Appendix 3Y - Philip KrauseAug 24
  • Preliminary Final Report including Appendix 4EAug 26
  • Annual Financial Results PresentationAug 26
All Mesoblast news releases↗

Follow Mesoblast into a list and get an email when it puts out news.

Follow Mesoblast
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer